CD274 and non-small cell lung carcinoma: In an open-label, randomized, phase 3 trial (CheckMate 227), the researchers demonstrated longer PFS time in NSCLC patients with a high TMB (defined as ≥10 mut/Mb), regardless of PD-L1 expression or tumor type (HR, 0.58; 95% CI, 0.41–0.81) (20).